Ulotaront


Trace amine-associated receptor 1 (TAAR1) full agonist with serotonin 5-HT1A receptor partial agonism

A first-in-class TAAR1/5-HT1A dual agonist discovered through phenotypic screening, developed for schizophrenia under FDA Breakthrough Therapy Designation, and distinguished from all approved antipsychotics by the absence of dopamine D2 and serotonin 5-HT2A receptor antagonism.

Abstract

Ulotaront (SEP-363856) is a thienopyran-based small molecule and the first trace amine-associated receptor 1 (TAAR1) agonist to reach Phase 3 clinical development for the treatment of schizophrenia. Discovered through a target-agnostic phenotypic screening collaboration between PsychoGenics and Sunovion Pharmaceuticals (now Sumitomo Pharma), ulotaront was identified using the SmartCube automated behavioral platform rather than rational design against TAAR1, and its molecular target was subsequently deconvoluted to reveal full agonism at human TAAR1 (EC50 approximately 38 to 140 nM, Emax approximately 101 to 109 percent) and partial agonism at the serotonin 5-HT1A receptor (EC50 approximately 2.3 micromolar, Emax approximately 75 percent). The compound is not an antagonist at either the dopamine D2 or the serotonin 5-HT2A receptor, the two canonical targets of all currently approved first-generation and second-generation antipsychotics. This mechanistic distinction positions ulotaront as a fundamentally novel pharmacological approach to psychotic disorders, with a preclinical and early clinical profile that suggests potential advantages in the avoidance of extrapyramidal symptoms, metabolic syndrome, hyperprolactinemia, and sedation that limit the tolerability of existing antipsychotic therapies.

The compound prevented olanzapine-induced weight gain in rodents and demonstrated no effect on prolactin release. Pharmacokinetics are characterized by rapid oral absorption, greater than 70 percent bioavailability in preclinical species, high blood-brain barrier penetration (brain concentrations approximately threefold higher than plasma), a median effective half-life of approximately 7 hours in humans supporting once-daily dosing, and predominant hepatic metabolism through CYP2D6. The compound received FDA Breakthrough Therapy Designation in May 2019 on the basis of a positive Phase 2 randomized controlled trial (Koblan et al., 2020) in 245 acutely psychotic adults with schizophrenia, in which ulotaront at 50 to 75 mg/day produced a statistically significant reduction in Positive and Negative Syndrome Scale (PANSS) total score of 17.2 points versus 9.7 points on placebo at four weeks (effect size 0.45, p less than 0.001), with concurrent improvement on negative symptom, depressive symptom, and global severity measures. A 26-week open-label extension demonstrated sustained improvement (PANSS total reduction of 41.8 points from double-blind baseline) with a favorable metabolic and movement disorder safety profile.

The Phase 3 DIAMOND program, however, produced negative results. DIAMOND 1 (ulotaront 50 and 75 mg/day versus placebo in 435 patients) and DIAMOND 2 (ulotaront 75 and 100 mg/day versus placebo in 464 patients) both failed to meet their primary endpoints at six weeks, with large placebo responses potentially masking the therapeutic signal. Additional Phase 3 studies (DIAMOND 3, long-term extension, and a switch study versus quetiapine) were planned or ongoing at the time of the negative readouts. Despite the Phase 3 setback in schizophrenia, ulotaront continues in Phase 2/3 development for generalized anxiety disorder and as adjunctive therapy in major depressive disorder, reflecting the broader neuropsychiatric potential of the TAAR1 mechanism. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph